Ergomed is delighted to announce that Dr. Elliot Brown, one of the original founders of PrimeVigilance, has offered his deep expertise and time to help with the evaluation and interpretation of safety data from clinical studies in Covid-19 as a consultant. Dr. Brown has worked for over 30 years as a drug safety and risk […]
Ergomed is delighted to announce that Dr. Elliot Brown, one of the original founders of PrimeVigilance, has offered his deep expertise and time to help with the evaluation and interpretation of safety data from clinical studies in Covid-19 as a consultant.
Dr. Brown has worked for over 30 years as a drug safety and risk management specialist, holding senior positions in the pharmaceutical industry and as an EU regulator and subsequently acting as a consultant to many companies and government regulatory bodies. Until recently he was an honorary safety adviser to the World Health Organization (WHO), and he is currently Associate Editor of the International Journal of Risk and Safety in Medicine.
Dr.Brown says: “I am really pleased to have this opportunity to be of some help during the pandemic by supporting PrimeVigilance and Ergomed in their valuable work on clinical trials involving COVID-19.”
Ergomed is very appreciative of Dr. Brown’s offer to share his wealth of global drug safety experience with us and our clients, helping to bring success in the fight against COVID-19.
